KAIROS PHARMA, LTD. Additional Collateral, Aggregate Fair Value
KAIROS PHARMA, LTD. (KAPA) had Additional Collateral, Aggregate Fair Value of $500.00 thousand as of 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes
us-gaap:AdditionalCollateralAggregateFairValue · last filed 2026-03-31
- 2024-12-31: Additional Collateral, Aggregate Fair Value $500.00K.
| Period end | Additional Collateral, Aggregate Fair Value |
|---|---|
| 2024-12-31 | $500.00K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |